Plasma oxytocin changes in response to low-dose MDMA vs. placebo in patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls – the OxyMAX Study

Physiological interventional study (übriger klinischer Versuch, Risk category B, no IMP). The aim of this study is to investigate plasma oxytocin in response to low-dose MDMA as a physiological stimulating agent. We do not aim to use MDMA as a medication or to develop it into a medication.